Cover Image
市場調查報告書

胃動力失調:開發中產品分析

Gastric Motility Disorder - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 253664
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
胃動力失調:開發中產品分析 Gastric Motility Disorder - Pipeline Review, H2 2014
出版日期: 2014年09月10日 內容資訊: 英文 37 Pages
簡介

胃動力失調的症狀有慢性嘔吐、噁心、痙攣、飽脹感、胃灼熱、腹部膨脹、飯後下痢等。

本報告提供胃動力失調治療藥的開發情形相關調查,提供開發中的產品概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢等。

簡介

  • 調查範圍

胃動力失調概要

治療藥的開發

  • 開發中的產品概要
  • 開發中產品比較分析

胃動力失調:企業開發中的治療藥

胃動力失調:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

胃動力失調:企業開發中的產品

胃動力失調的治療藥開發企業

  • Theravance, Inc.
  • Helsinn Healthcare S.A.
  • Concert Pharmaceuticals, Inc.
  • Targacept, Inc.
  • ChironWells GmbH

胃動力失調:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • velusetrag
  • ipamorelin
  • TD-8954
  • TC-6499
  • 小分子

胃動力失調:最近的開發平台趨勢

胃動力失調:暫停中的計劃

胃動力失調:開發中止的產品

胃動力失調:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5521IDB

Summary

Global Markets Direct's, 'Gastric Motility Disorder - Pipeline Review, H2 2014', provides an overview of the Gastric Motility Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Motility Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Motility Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastric Motility Disorder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastric Motility Disorder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastric Motility Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastric Motility Disorder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastric Motility Disorder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastric Motility Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastric Motility Disorder Overview
  • Therapeutics Development
    • Pipeline Products for Gastric Motility Disorder - Overview
    • Pipeline Products for Gastric Motility Disorder - Comparative Analysis
  • Gastric Motility Disorder - Therapeutics under Development by Companies
  • Gastric Motility Disorder - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Gastric Motility Disorder - Products under Development by Companies
  • Gastric Motility Disorder - Companies Involved in Therapeutics Development
    • Helsinn Healthcare S.A.
    • Targacept, Inc.
    • ChironWells GmbH
  • Gastric Motility Disorder - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • velusetrag - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipamorelin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TD-8954 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TC-6499 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Bowel Motility Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gastric Motility Disorder - Recent Pipeline Updates
  • Gastric Motility Disorder - Dormant Projects
  • Gastric Motility Disorder - Discontinued Products
  • Gastric Motility Disorder - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2012: RaQualia Pharma Initiates First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
      • Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastric Motility Disorder, H2 2014
  • Number of Products under Development for Gastric Motility Disorder - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Gastric Motility Disorder - Pipeline by Helsinn Healthcare S.A., H2 2014
  • Gastric Motility Disorder - Pipeline by Targacept, Inc., H2 2014
  • Gastric Motility Disorder - Pipeline by ChironWells GmbH, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Gastric Motility Disorder Therapeutics - Recent Pipeline Updates, H2 2014
  • Gastric Motility Disorder - Dormant Projects, H2 2014
  • Gastric Motility Disorder - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Gastric Motility Disorder, H2 2014
  • Number of Products under Development for Gastric Motility Disorder - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top